Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

Background Non-invasive fibrosis scores are not yet validated in the newly defined metabolic associated fatty liver disease (MAFLD). Aim To evaluate diagnostic performance of four non-invasive including aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4), body mass index, aminotransferase/alanine ratio, diabetes score (BARD), and nonalcoholic (NFS) patients with MAFLD. Methods Consecutive histologically confirmed MAFLD were included. The discrimination ability different was compared. Results A total 417 included; 156 (37.4%) them had advanced (Metavir ? F3). area under receiver operating characteristic curve FIB-4, NFS, APRI, BARD for predicting 0.736, 0.724, 0.671, 0.609, respectively. FIB-4 NFS similar (P = 0.523), while difference between APRI 0.001) Conclusion do perform well could be more useful, but a new threshold is needed. Novel scoring systems required